EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year

Mohamed Abdelgader iD, Roann Khalid iD, Kartik Yadav iD, Sama Ehab Salah Ahmed iD, Murugapathy Veerasamy iD, Arka Das iD, Heerajnarain Bulluck iD

Reviews in Cardiovascular Medicine · 24.07.2026 · 27 (7)

DOI: 10.31083/rcm51947 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 24.07.2026. Verfasst von Mohamed Abdelgader und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The early period following percutaneous coronary intervention (PCI), particularly the first days to weeks after stent implantation, is characterized by heightened device-related thrombotic risk, and dual antiplatelet therapy (DAPT) during this phase is well established. With contemporary drug-eluting stents (DES) and abbreviated DAPT strategies, late stent-related events have become less frequent, and long-term risk increasingly reflects underlying systemic atherosclerotic disease. Beyond 12 months, the risk profile shifts further: late events increasingly reflect progressive atherosclerosis and systemic vascular disease rather than stent-related thrombosis. This review synthesizes contemporary evidence on long-term antiplatelet and antithrombotic therapy after PCI, with a focus on the period beyond one year. We evaluate the data supporting for lifelong aspirin as the traditional default strategy, as well as the emerging evidence that P2Y12 inhibitor monotherapy may be superior to aspirin in selected post-PCI populations (HOST-EXAM, HOST-EXAM Extended, PANTHER, SMART-CHOICE 3). This review also examines the role of prolonged DAPT in selected high-risk patients (DAPT Trial, PEGASUS–Thrombolysis in Myocardial Infarction (TIMI) 54) and the paradigm of dual-pathway inhibition with low-dose rivaroxaban plus aspirin (COMPASS, VOYAGER-peripheral artery disease (PAD)). In addition, the review considers protease-activated receptor (PAR) antagonism (TRA 2°P–TIMI 50) and precision-based strategies, including CYP2C19 genotype-guided therapy. Special populations, such as patients with diabetes, chronic kidney disease (CKD), polyvascular disease, and those requiring concomitant oral anticoagulation, present distinct long-term management challenges. Thus, novel targets, including factor XIa inhibitors and PAR-4 antagonists, may further refine the antithrombotic approach. Overall, the optimal long-term strategy after PCI is increasingly defined not by fixed timelines but by the dynamic balance between ischemic and bleeding risk.

Schlagwörter

Stichwörter der Autor:innen

aspirinclopidogrelcolchicineicosapent ethylmonotherapypercutaneous coronary interventionpharmacogeneticsrivaroxabansecondary preventionthrombosis

Autor:innen und Institutionen

  • Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK.
  • General Medicine, King's College Hospital NHS Foundation Trust, SE5 9RS London, UK.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.

ORCID-Profile: Mohamed Abdelgader, Roann Khalid, Kartik Yadav, Sama Ehab Salah Ahmed, Murugapathy Veerasamy, Arka Das, Heerajnarain Bulluck

Zitieren

APA

Abdelgader, M., Khalid, R., Yadav, K., Ahmed, S. E. S., Veerasamy, M., Das, A., & Bulluck, H. (2026). Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year. Reviews in Cardiovascular Medicine, 27(7). https://doi.org/10.31083/rcm51947

Vancouver

Abdelgader M, Khalid R, Yadav K, Ahmed SES, Veerasamy M, Das A, et al. Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year. Reviews in Cardiovascular Medicine. 2026;27(7). doi:10.31083/rcm51947

BibTeX
@article{Abdelgader2026,
  author = {Abdelgader, Mohamed and Khalid, Roann and Yadav, Kartik and Ahmed, Sama Ehab Salah and Veerasamy, Murugapathy and Das, Arka and Bulluck, Heerajnarain},
  title = {Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  volume = {27},
  number = {7},
  doi = {10.31083/rcm51947}
}
Kostenlos starten →